American Medical Strategies has released its fourth annual list of the five most researched diagnoses in its PredictDx system. Three of the top five spots were held by cancers in 2017.
For the second year in a row, breast cancer was the most commonly researched diagnosis among users of PredictDx. That finding is not surprising, as breast cancer is the most commonly diagnosed non-skin cancer among women. Colon cancer held the third spot and prostate cancer held the fourth spot, reflecting the prevalence and cost of cancer in America.
Chronic renal failure/end stage renal disease (ESRD) was the second most researched diagnoses in 2017. Dilated cardiomyopathy/congestive heart failure (CHF) was fifth.
The list reflected two changes from the previous year. In 2016, colon cancer and CHF didn’t appear in the top five. In that year, the third most searched diagnosis was Non-Hodgkin lymphoma and the fifth was multiple myeloma (cancer of the white blood cells).
AMS included data in its report about the average cost of treatment for each of the top five diagnoses. Of those five, ESRD requires the most expensive treatment. The national average cost for center-based hemodialysis is $338,625 – $420,525, according to the report.
In many of the above cases, the conditions are long-term, taking years of treatment, or they may be chronic, lasting throughout the person’s life. If you have a self-funded plan, ensuring catastrophic care is in place will ensure that if someone in your employee pool experiences one of these ailments, both your organization as well as your employee are taken care of. Your stop loss insurance carrier may also be able to suggest resources that will assist in cost containment for these diagnoses.
At Stop Loss Insurance Brokers Inc. we’re staying on top of trends and insights involving insurance and claims as they relate to stop loss insurance. To learn more on how you can save money while increasing coverage, contact us today.